CD274 and neoplasm: We could only determine the PD-L1 status in tumor cells in two patients from our series, one of them with a TPS = 0 and the other with a TPS = 5%, and both received nivolumab in the fourth and third line, respectively, achieving very durable benefit which is still ongoing.